A drug that is commonly used to treat bone marrow cancer may help to restore hair in patients with an autoimmune disease that causes hair loss, a new study has found. The study, published online August 17 in the journal Nature Medicine, found that the drug ruxolitinib (brand name: Jakafi) helped to restore hair growth in a small number of patients with alopecia areata.
The FDA has approved Jardiance (empagliflozin) to be used to control blood sugar levels in the management of diabetes. The drug, developed by the Connecticut-based Boehringer Ingelheim Pharmaceuticals, was tested in seven clinical trials, demonstrating success in improving blood sugar levels compared to a placebo. "Jardiance provides an additional treatment option for the care of patients . . ."
The FDA halted treatment of the ebola treatment called TKM-Ebola, developed by the Canadian pharmaceutical company Tekmira. In January, the company began its phase one trials, and was added to the FDA's fast track schedule, but in July the government agency reversed course, stopping the phase one trials. The FDA is now asking Tekmira to give it more info on how the drug interacts with the body.
The FDA has approved an over-the-counter formulation of the drug Flonase aimed specifically at allergy relief. The drug, produced by GlaxoSmithKline, will be the second major nasal steroid approved for over the counter sales by the FDA. The first such drug approved by the agency was Nasacort 24Hr and both drugs are approved for symptoms including nasal congestion, runny nose, sneezing and more.
Alcon's Simbrinza has been approved in the European Union to treat those living with glaucoma. The drug combines two approved therapies, Brinzolamide 10mg/mL and Brimonidine 2mg/mL, in one eye drop formula. Glaucoma is a group of diseases that damage the eye's optic nerve and can result in vision loss and blindness.
Acetaminophen may not help treat lower-back pain, according to research conducted at the University of Sydney. The study, published in the journal the Lancet, collected data on over 1,600 people diagnosed with acute back pain. Researchers gave one group a placebo pill and another group acetaminophen and found that the latter offered no substantial pain relief compared to the former.